Giant Intracranial Aneurysm Criteria
A giant intracranial aneurysm is defined as any intracranial aneurysm with a diameter ≥25 mm. This is the universally accepted threshold that distinguishes giant aneurysms from large aneurysms (which are 10-24 mm) 1, 2, 3, 4, 5, 6.
Key Defining Characteristics
The 25 mm cutoff is consistent across all contemporary literature and represents a critical size threshold because:
- Epidemiology: Giant aneurysms represent only 3-5% of all intracranial aneurysms in adults 4, 5
- Age of presentation: Typically manifest during the 5th-7th decades of life 4
- Clinical behavior: These lesions behave fundamentally differently than smaller aneurysms, predominantly causing mass effect rather than hemorrhage 4
Clinical Presentation Patterns
Giant aneurysms present differently than their smaller counterparts:
- Mass effect symptoms: 78.7% of patients present with compressive symptoms 2
- Cerebral ischemia: 8.3% 2
- Intracranial hemorrhage: Only 3% 2
- Seizures: 2.8% 2
This contrasts sharply with smaller aneurysms where rupture and hemorrhage are more common presenting features.
Important Clinical Pitfalls
Do not confuse giant aneurysms with large aneurysms. The AHA/ASA guidelines reference aneurysms ≥10 mm as "large" in treatment discussions 7, but this is a different category. The specific 25 mm threshold for "giant" designation carries distinct prognostic and treatment implications.
Giant partially thrombosed aneurysms can mimic other lesions on imaging, including meningiomas, pituitary adenomas, craniopharyngiomas, and gliomas 4. Always obtain comprehensive vascular imaging (CTA or DSA) when evaluating any large intracranial mass.
Treatment Implications of Size
The giant designation (≥25 mm) fundamentally alters treatment planning:
- Higher surgical complexity: Microsurgical management shows 79.2% good outcomes but requires bypass procedures in 24.7% of cases 1
- Location-specific morbidity: Supraclinoidal ICA giant aneurysms carry 28% morbidity and 12% mortality, while infraclinoidal ICA aneurysms have only 10% morbidity 1
- Endovascular challenges: While less morbid initially, endovascular treatment of giant aneurysms has a 20% retreatment rate compared to 96.8% complete occlusion with microsurgery 1
The size criterion of ≥25 mm is absolute and non-negotiable in classification, though treatment decisions must account for location, rupture status, and patient factors beyond size alone.